Chikungunya virus (CHIKV) is transmitted by several species of mosquitos, which are also known to transmit Dengue, Zika and Yellow fever. Symptoms include joint pain, swelling and stiffness of joints, nausea, fever, fatigue and head ache. Arthritis is the most common direct consequence of infection. The virus has spread from Africa, Asia and Islands in the Pacific and Indian Ocean to Southern Europe, the Americas and the Caribbean.
There currently is no vaccine against Chikungunya infection.
Mymetics' Chikungunya vaccine approach
Mymetics is developing a preventive CHIKV vaccine consisting of an enveloped virus like particle (virosome) which contains the most import antigens and a possibility to include an adjuvant.
Latest Results and Next Steps
We are currently at the end of the discovery program which has mainly focused on production, yield and feasibility.
In the second half of 2017 we plan to enter into preclinical studies.